Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-05-02
2006-05-02
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S024100, C536S023720
Reexamination Certificate
active
07037716
ABSTRACT:
The invention provides improved methods and products based on adenoviral materials which can advantageously be used in gene therapy. In one aspect, an adenoviral vector is provided having no overlap with a suitable packaging cell line. The suitable packaging cell line is another aspect. The combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. Another aspect embodies an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Furthermore, a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, all of which have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system.
REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude et al.
patent: 4497796 (1985-02-01), Salser et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5208149 (1993-05-01), Inouye
patent: 5378618 (1995-01-01), Sternberg et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5545522 (1996-08-01), Van Gelder et al.
patent: 5652224 (1997-07-01), Wilson et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5753500 (1998-05-01), Shenk et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5935935 (1999-08-01), Connelly et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6040174 (2000-03-01), Imler et al.
patent: 6238893 (2001-05-01), Hoeben et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6413776 (2002-07-01), Vogels et al.
patent: 6602706 (2003-08-01), Fallaux et al.
patent: A-28533/95 (1996-03-01), None
patent: 2053187 (1993-04-01), None
patent: 2117668 (1995-09-01), None
patent: 95201611.1 (1995-06-01), None
patent: 95201728.3 (1995-06-01), None
patent: 2 707 664 (1995-01-01), None
patent: WO 91/02804 (1991-03-01), None
patent: WO 94/12649 (1994-06-01), None
patent: WO 94/23582 (1994-10-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 95/00655 (1995-01-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 96/16676 (1996-06-01), None
patent: WO 96/18418 (1996-06-01), None
patent: WO 96/33280 (1996-10-01), None
patent: WO 96/40955 (1996-12-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 97/00947 (1997-01-01), None
patent: WO 97/04119 (1997-02-01), None
patent: WO 97/05255 (1997-02-01), None
Amalfitano et al., “Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors,”Proc. Natl. Acad. Sci. USA, 93:3352-3356, Apr. 1996.
Amalfitano et al., “Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy,”Gene Therapy, 4:258-263,1997.
Armentano et al., “Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion,”Human Gene Therapy, 6:1343-1353, Oct. 1995.
Berkner, Expression of Heterologous Sequences in Adenoviral Vectors, Current Topics in Microbiology and Immunology, vol. 158, Springer-Verlag Berlin Heidelberg 1992.
Blaese et al., Vectors in Cancer therapy: how will they deliver?,Cancer Gene Therapy, vol. 2, No. 4, 1995, pp. 291-297.
Bout et al., “In vivo adenovirus-mediated transfer of human CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity and safety,”Gene Therapy1, pp. 385-394, 1994.
Bout et al., “Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium,”Human Gene Therapy, 5:3-10, 1994.
Brough et al., “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4,”Journal of Virology, 70(9):6497-6501, Sep. 1996.
Brough et al., Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4;Abstract Book CSH Conference on Gene Therapy, 42, 1996.
Brough et al., “Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein,”Virology, 190:624-634, 1992.
Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5,”Journal of Virology, 69(11):6627-6633, Nov. 1995.
Fallaux et al., “Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors,”Human Gene Therapy, 7:215-222, 1996.
Fisher et al., “Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis,”Virology, 217:11-22, 1996.
Gao et al., “Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy,”Journal of Virology, 70(12):8934-8943, Dec. 1996.
Gorziglia et al., “Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy,”Journal of Virology, 70(6):4173-4178, Jun. 1996.
Haddada et al., “Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice,”Human Gene Therapy, 4:703-711, 1993.
Hardy et al., “Construction of Adenovirus Vectors through Cre-Iox Recombination,”Journal of Virology, 71(3):1842-1849, Mar. 1997.
Hehir et al., “Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications to Prevent Their Occurrence,”Journal of Virology, 70(12):8459-8467, Dec. 1996.
Imler et al., “Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors,”Gene Therapy, 3:75-84, 1996.
Kornberg, Arthur, “DNA Replication,” W.H.Freeman and Company, San Francisco, 4 pages (double sided).
Krougliak et al., “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants,”Human Gene Therapy, 6:1575-1586, Dec. 1995.
Lieber et al., “Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo,”Journal of Virology, 70:8944-8960, Dec. 1996.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, 5 pages.
Sabatie et al., “Process Development for the Production of Second Generation Adenovirus Vectors for Gene Transfer in Clinical Protocols,”Abstract Book 14thMeeting on Animal Cell Technolgoy, BI3, 1996.
Schaack et al., “Adenivorus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines,”Journal of Virology, 69(7):4079-4085, Jul. 1995.
Stratford-Perricaudet et al., Gene transfer into animals: the promise of adenovirus, Human Gene Transfer, 1991, vol. 219, pp. 51-61.
Vanhaesebroeck et al., “Modulation of Cellular Susceptibility to the Cytotoxic/Cytostatic Action of Tumor Necrosis Factor by Adenovirus E1 Gene Expression Is Cell Type-Dependent,”Virology, 176(2), pp. 362-368, Jun. 1990.
Vincent et al., “Herpes Simplex Virus Thymidine Kinase Gene Therapy for Rat Malignant Brain Tumors,”Human Gene Therapy7:197-205, Jan. 20, 1996.
Vincent et al., “Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene,”J. Neurosurg., vol. 85, pp. 648-65
Bout Abraham
Vogels Ronald
Crucell Holland B.V.
Guzo David
TraskBritt
LandOfFree
Packaging systems for human recombinant adenovirus to be... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Packaging systems for human recombinant adenovirus to be..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Packaging systems for human recombinant adenovirus to be... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540464